Avenue Therapeutics Inc Financials

ATXI

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Avenue Therapeutics Inc (ATXI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Avenue Therapeutics Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.77x

For every $1 of reported earnings, Avenue Therapeutics Inc generates $0.77 in operating cash flow (-$9.0M OCF vs -$11.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

N/A

Free Cash Flow

N/A

Net Income

-$11.7M

YoY-11.5%

Avenue Therapeutics Inc reported -$11.7M in net income in fiscal year 2024. This represents a decrease of 11.5% from the prior year.

EPS (Diluted)

N/A

Cash & Debt

$2.6M

YoY+45.5%

5Y CAGR-21.6%

Avenue Therapeutics Inc held $2.6M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

Avenue Therapeutics Inc had 2M shares outstanding in fiscal year 2024. This represents an increase of 517.8% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$6.6M

YoY+8.4%

5Y CAGR-21.4%

Avenue Therapeutics Inc invested $6.6M in research and development in fiscal year 2024. This represents an increase of 8.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ATXI Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$6.6M+8.4%	$6.1M+127.2%	$2.7M+115.2%	$1.3M-56.2%	$2.9M-87.1%	$22.2M
SG&A Expenses	$4.6M+11.0%	$4.2M-21.8%	$5.3M+115.2%	$2.5M+5.8%	$2.3M-23.6%	$3.1M
Operating Income	-$11.3M+22.4%	-$14.5M-80.8%	-$8.0M-115.2%	-$3.7M+28.3%	-$5.2M+80.2%	-$26.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	N/A	N/A	N/A
Net Income	-$11.7M-11.5%	-$10.5M-195.3%	-$3.6M+4.8%	-$3.7M+27.6%	-$5.2M+80.1%	-$25.9M
EPS (Diluted)	N/A	N/A	N/A	$-0.22	$-0.31	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$0-100.0%	$1.4M	N/A	N/A	$0	$0	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$177K-7.8%	$192K-53.3%	$411K	N/A	$2.3M+71.0%	$1.4M-43.1%	$2.4M	N/A
SG&A Expenses	$547K-40.2%	$915K-38.8%	$1.5M	N/A	$829K-43.3%	$1.5M+11.1%	$1.3M	N/A
Operating Income	-$724K-343.8%	$297K+115.6%	-$1.9M	N/A	-$3.2M-11.8%	-$2.8M+23.9%	-$3.7M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$683K-303.9%	$335K+118.1%	-$1.9M	N/A	-$3.1M-14.3%	-$2.7M+38.0%	-$4.3M+30.5%	-$6.2M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ATXI Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$2.7M+44.4%	$1.9M-73.0%	$6.8M+72.9%	$4.0M+22.0%	$3.2M-63.6%	$8.9M
Current Assets	N/A	N/A	N/A	$4.0M+22.0%	$3.2M	N/A
Cash & Equivalents	$2.6M+45.5%	$1.8M-73.4%	$6.7M+78.3%	$3.8M+20.1%	$3.1M-64.2%	$8.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	-$125K-146.6%	$268K-92.5%	$3.6M+603.1%	$509K-42.6%	$886K-58.1%	$2.1M
Current Liabilities	$816K-31.8%	$1.2M-66.6%	$3.6M+603.1%	$509K-42.6%	$886K-58.1%	$2.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.8M+76.8%	$1.6M-59.5%	$3.9M+13.2%	$3.5M+46.3%	$2.4M-65.3%	$6.8M
Retained Earnings	-$102.6M-12.8%	-$90.9M-12.9%	-$80.6M-4.6%	-$77.0M-5.1%	-$73.3M-7.6%	-$68.1M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$3.7M-10.5%	$4.2M+15.8%	$3.6M+34.5%	$2.7M+1.8%	$2.6M-47.4%	$5.0M+50.7%	$3.3M+78.9%	$1.9M
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$3.7M+11.5%	$3.3M-5.0%	$3.5M+35.0%	$2.6M-0.1%	$2.6M-47.2%	$4.9M+54.0%	$3.2M+79.1%	$1.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$168K+63.1%	$103K+22.6%	$84K+167.2%	-$125K-933.3%	$15K-98.7%	$1.2M+144.9%	$474K+76.9%	$268K
Current Liabilities	$1.4M+7.0%	$1.3M+5.3%	$1.3M+54.7%	$816K-16.1%	$973K-16.2%	$1.2M-17.8%	$1.4M+18.1%	$1.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.6M-12.3%	$4.1M+15.6%	$3.5M+25.5%	$2.8M+7.2%	$2.6M-45.2%	$4.8M+68.0%	$2.8M+79.3%	$1.6M
Retained Earnings	-$104.8M-0.7%	-$104.1M+0.3%	-$104.4M-1.8%	-$102.6M-1.5%	-$101.0M-3.1%	-$98.0M-2.8%	-$95.3M-4.8%	-$90.9M

ATXI Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$9.0M+4.5%	-$9.5M-24.4%	-$7.6M-102.6%	-$3.8M+18.7%	-$4.6M+82.4%	-$26.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0+100.0%	-$3.0M	$0	N/A	-$1.0M	$0
Financing Cash Flow	$9.8M+30.7%	$7.5M-28.6%	$10.5M+140.6%	$4.4M	$0-100.0%	$32.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$0-100.0%	$1.1M	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	$383K+317.6%	-$176K+85.2%	-$1.2M-55.2%	-$764K+73.6%	-$2.9M-28.2%	-$2.3M+27.8%	-$3.1M-34.3%	-$2.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	$0	$0+100.0%	-$5.0M	$0	$0
Financing Cash Flow	$0	$0-100.0%	$2.1M+175.2%	$761K+34.2%	$567K-85.7%	$4.0M-12.2%	$4.5M+14.8%	$3.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ATXI Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-437.7%+129.2pp	-566.9%-515.0pp	-51.9%+42.3pp	-94.2%+64.5pp	-158.7%+131.9pp	-290.6%
Current Ratio	N/A	N/A	N/A	7.78+4.1	3.66	N/A
Debt-to-Equity	-0.04-0.2	0.17-0.7	0.92+0.8	0.15-0.2	0.38+0.1	0.31
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	21.1%	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	23.9%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	8.3%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-18.3%-26.4pp	8.1%+59.6pp	-51.5%	N/A	-117.2%-63.2pp	-54.0%+77.1pp	-131.1%-103.0pp	-28.2%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.05+0.0	0.030.0	0.02+0.1	-0.04-0.1	0.01-0.2	0.24+0.1	0.170.0	0.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Restart Life NMLSF

$2.7M

Mosaic Immunoengineering Inc CPMV

$2.9M

Mynd Life Scienc MYNDF

$2.4M

Nascent Biotech NBIO

$3.3M

Algernon Health AGNPF

$1.9M

Frequently Asked Questions

Is Avenue Therapeutics Inc profitable?

No, Avenue Therapeutics Inc (ATXI) reported a net income of -$11.7M in fiscal year 2024.

What is Avenue Therapeutics Inc's operating cash flow?

Avenue Therapeutics Inc (ATXI) generated -$9.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Avenue Therapeutics Inc's total assets?

Avenue Therapeutics Inc (ATXI) had $2.7M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Avenue Therapeutics Inc spend on research and development?

Avenue Therapeutics Inc (ATXI) invested $6.6M in research and development during fiscal year 2024.

How many shares does Avenue Therapeutics Inc have outstanding?

Avenue Therapeutics Inc (ATXI) had 2M shares outstanding as of fiscal year 2024.

What is Avenue Therapeutics Inc's debt-to-equity ratio?

Avenue Therapeutics Inc (ATXI) had a debt-to-equity ratio of -0.04 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Avenue Therapeutics Inc's return on assets (ROA)?

Avenue Therapeutics Inc (ATXI) had a return on assets of -437.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Avenue Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Avenue Therapeutics Inc (ATXI) had $2.6M in cash against an annual operating cash burn of $9.0M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Avenue Therapeutics Inc's Piotroski F-Score?

Avenue Therapeutics Inc (ATXI) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Avenue Therapeutics Inc's earnings high quality?

Avenue Therapeutics Inc (ATXI) has an earnings quality ratio of 0.77x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.